A study of subjects with Psoriatic Arthritis to investigate the effectiveness of adalimumab introduction compared with methotrexate dose escalation

Update Il y a 5 ans
Reference: EUCTR2016-000191-21

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To compare the effectiveness based on the achievement of minimal disease activity (MDA) at Week 16 between subjects who had adalimumab introduced and those that had methotrexate (MTX) escalated to the highest recommended dose of 20–25 mg every week (ew) or highest tolerable dose up to 25 mg ew after inadequate disease control on the initial MTX therapy.


Inclusion criteria

  • Psoriatic Arthritis,Psoriatická artritida